NCT05968417招募中不适用
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
Institute of Cancer Research, United Kingdom1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2020年7月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Cell viability
研究概览
简要总结
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
- •Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
- •Participants aged 18 years of age or above
- •Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
排除标准
- •Participants unable to provide consent
- •Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
结局指标
主要结局
Cell viability
时间窗: 12 months
Myeloma cell viability when incubated with standard of care and novel compounds.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00897910Barbara Ann Karmanos Cancer Institute6
已完成
1 期
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple MyelomaMultiple MyelomaNCT00552396Innate Pharma32
Unknown
不适用
Bone Pain in Multiple Myeloma- a Translational StudyMultiple MyelomaNCT04273425Sheffield Teaching Hospitals NHS Foundation Trust35
进行中（未招募）
1 期
A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple MyelomaMultiple MyelomaNCT04499339Wuerzburg University Hospital38
Unknown
不适用
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omicsBortezomibMultiple MyelomaNCT04678089Beijing Chao Yang Hospital350